PharmAbcine Reveals Preclinical Results of 'Next-Generation Vascular Disease Agent' at American Academy of Ophthalmology Meeting

[Asia Economy Reporter Hyunseok Yoo] Pamemxin, a bio company specializing in antibody drug development, will disclose the non-clinical results of its next-generation vascular disease drug candidate (PMC-403).

On the 26th, Pamemxin announced that it will present the non-clinical results at the annual scientific meeting of the Association for Research in Vision and Ophthalmology (ARVO), held online in the United States on the 5th of next month.

PMC-403 is a vascular stabilizing agent that activates the Tie2 receptor to normalize abnormal neovascularization. Tie2 is a receptor for the proteins Angiopoietin-1 and 2 (Ang-1,2), which regulate blood vessel formation and promote vascular maturation and stability. PMC-403 has a mechanism that restores small holes in the vascular wall or abnormally connected vessels through activation of Tie2.

A Pamemxin company official said, “PMC-403 is expected to overcome the problems of existing anti-angiogenic drugs used for vascular disease treatment as a next-generation vascular disease therapeutic. Currently, there are no approved drugs with Tie2 efficacy and mechanism of action, and among ongoing non-clinical pipelines, PMC-403 is the only antibody candidate, which highly increases its potential as a First-in-Class innovative drug.”

In August last year, Pamemxin signed a contract (CDMO) with Samsung Biologics for the production of clinical and non-clinical samples of PMC-403, receiving services covering the entire contract development and manufacturing process, including cell line development, process development, clinical sample production, and support for Investigational New Drug (IND) application submission. Pamemxin aims to complete the non-clinical toxicity tests required for the IND submission for PMC-403’s Phase 1 clinical trial this year and to start clinical trials next year.

Yujinsan, CEO of Pamemxin, stated, “Attending ARVO this time is significant as it validates the potential of Pamemxin’s non-oncology candidate at a global academic conference. With the rapid aging population, demand for treatments and drugs for the three major elderly ophthalmic diseases (macular degeneration, glaucoma, cataracts) is increasing, and through this conference presentation, we will widely promote the value of PMC-403.”

Meanwhile, ARVO, which Pamemxin is participating in, is the world’s most prestigious academic conference in ophthalmology and vision science, with 11,000 researchers from over 75 countries participating. Since its inception in 1930, ARVO has been selected as one of the world’s top 50 medical academic conferences. It actively conducts related research, paper publication, and educational activities, presenting over 7,000 basic and clinical research papers annually at its regular meetings.

This event will be held online due to the impact of COVID-19. It will take place from the 1st to the 7th of next month, U.S. local time. Abstracts for ARVO 2021 will be available on the official website after the conference opens. Pamemxin’s online poster will be presented on the 5th of next month and will be available until June 30.

This content was produced with the assistance of AI translation services.